This article reviews the scope, key principles, methodological expectations, and regulatory implications of ICH E20, and ...

From Genryo’s Sidewinder technology to the Festival of Genomics & Biodata in the UK earlier this year – AI might be trending, ...

Novo Nordisk is running other phase 2 trials of the drug, including the 8212-Preserved study in heart failure with preserved ...

The agreement with Sino Bio, via its subsidiary Chia Tai Tianqing Pharma (CTTQ), allies GSK with a company that is one of ...

Novo Nordisk has been handed a crucial legal win by China's Supreme Court, which has upheld the company's patent protection on GLP-1 agonist semaglutide used for diabetes and weight loss. The court in ...

Partner Therapeutics' Bizengri has been approved for a new indication, a rare form of bile duct cancer, just two days after ...

Roche has been working with US AI specialist PathAI for around five years, and has now upgraded that partnership with an offer to buy the company outright for $1.05 billion. Already a giant in the ...

Bayer has agreed terms for its first biopharma acquisition in years, paying $300 million upfront for privately-held US biotech Perfuse Therapeutic and its novel drug implant for eye diseases. The deal ...

Having already committed last year to capital investments of $27 billion in the US to ward off the threat of tariffs, Eli Lilly has upped the ante. The Indianapolis-headquartered pharma group pledged ...

In 2022, obesity contributed just 1% of the projected value of pharma industry pipeline, as calculated by Deloitte. Now, its share has rocketed to 25%, grouped around just a few drugs with the ...

Novartis has a much-anticipated approval for its spinal muscular atrophy (SMA) treatment onasemnogene abeparvovec in the US, getting a green light for a new version that can make more patients ...